Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Diegy schreef op 4 november 2016 16:48 :
Ik ben in ieder geval zojuist ingestapt op 19,45. De verkoop zal misschien nabeurs of volgende week bekend worden gemaakt en reken maar dat dat nieuws de koers fors hoger zal zetten.
Zeg het eerlijk voor mij ben je een held. Sterkte en Toi Toi Toi. Ruud.. PS hou van een gokje maar dit zo voor het weekend?
Valeant boekt verlies Canadese farmaceut boekt stevige impairment. (ABM FN-Dow Jones) Valeant Pharmaceuticals International heeft in het afgelopen kwartaal een verlies geleden op een lagere omzet. Dit meldde de Canadese farmaceut dinsdag die ook zijn outlook wijzigde. In het kwartaal dat eind september eindigde, werd onder aan de streep een verlies geboekt van 1.218 miljoen dollar tegenover een winst van 49,5 miljoen dollar een jaar eerder, een afname die Valeant vooral toeschreef aan een voorziening voor een impairment van 1.049 miljoen dollar, die voornamelijk verband hield met Salix. Eerder deze maand berichtten media dat Valeant Salix voor 10 miljard dollar van de hand zou willen doen. Salix werd circa anderhalf jaar geleden door Valeant ingelijfd voor 11 miljard dollar, maar het bedrijf gaat gebukt onder een stevige schuldenlast van meer dan 30 miljard dollar. De aangepaste winst per aandeel daalde van 2,14 naar 1,40 dollar terwijl de omzet op jaarbasis met bijna 300 miljoen dollar afnam. Op kwartaalbasis steeg de omzet van 2,42 miljard dollar in het tweede kwartaal naar 2,48 miljard dollar. De nieuwe CEO Joseph Papa die in mei Michael Pearson opvolgde, zei in een verklaring "dat het bedrijf vorderingen boekt op weg naar het nieuwe Valeant". Outlook Valeant herzag dinsdag de outlook voor heel het boekjaar en rekent nu op een winst per aandeel van tussen de 5,30 en 5,50 dollar tegen eerst tussen de 6,60 en 7,00 dollar en een omzet van tussen de 9,55 en 9,65 miljard dollar tegen een eerdere guidance die lag tussen de 9,9 miljard en 10,1 miljard dollar. Het aangepaste operationele resultaat wordt nu verwacht uit te komen tussen 4,25 miljard en 4,35 miljard dollar waarvoor eerste nog werd gemikt op een range tussen de 4,80 miljard en 4,95 miljard dollar. Het aandeel Valeant sloot maandag 0,9 procent lager. Door: ABM Financial News.info@abmfn.nl Redactie: +31(0)20 26 28 999 Copyright ABM Financial News. All rights reserved (END) Dow Jones Newswires
Valeant Pharmaceuticals To Participate In Healthcare Conferences Thu November 10, 2016seekingalpha.com/pr/16663853-valeant-... LAVAL, Quebec, Nov. 10, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (VRX) (NYSE: VRX) (TSX: VRX) today announced that Joseph C. Papa, Chairman and CEO, will participate in the following healthcare conferences: *Stifel 2016 Healthcare Conference on Tuesday, November 15 , 2016 at 8:00 a.m. ET at the New York Palace Hotel; *Guggenheim 4th Annual Boston Healthcare Conference on Tuesday, December 13 , 2016 at 11:45 a.m. ET at the Intercontinental Boston; and, *BMO Prescriptions for Success Healthcare Conference on Wednesday, December 14 , 2016 at 1:30 p.m. ET at the InterContinental Barclay Hotel in New York City. A live webcast and audio archive of the events will be available on Valeant's Investor Relations website and via this URL: ir.valeant.com/investor-relations/eve...
Healthcare ratings roundup - downgradeswww.seekingalpha.com/news/3223470 Valeant Pharmaceuticals (NYSE:VRX) downgraded to Neutral from Buy by Rodman & Renshaw. Price target lowered to $23 (37% upside) from $81
NEW YORK, Nov 17 - Two former executives were arrested on Thursday on charges related to the investigation of drugmaker Valeant Pharmaceuticals International Inc's ties to a specialty pharmacy company. Gary Tanner, a former Valeant executive, and Andrew Davenport, the former chief executive of specialty pharmacy Philidor Rx Services LLC, were charged in a criminal complaint filed in Manhattan federal court, prosecutors said. The Federal Bureau of Investigation arrested Tanner, 39, and Davenport, 48, on Thursday morning at their residences in Phoenix and Philadelphia, respectively, an agency spokeswoman said. They were expected to appear in court later in the day. Thursday's complaint accused Tanner of secretly working with Davenport to promote Philidor's business with the goal of consummating a purchase option agreement between Valeant and Philidor. The agreement resulted in tens of millions of dollars for Davenport personally and close to $10 million in secret kickback payments to Tanner, the complaint said. Lawyers for the defendants could not be immediately identified. A Valeant representative had no immediate comment. The development is the latest event to hit Laval, Quebec-based Valeant, whose stock has plunged more than 90 percent since August 2015 amid intense criticism of its drug pricing and business practices and various investigations. Valeant, whose biggest investor is Bill Ackman's Pershing Square Capital Management, has disclosed receiving subpoenas seeking information related to its ties to Philidor and its accounting treatment for sales by specialty pharmacies. Valeant shares fell 5 percent, or 88 cents, to $16.99 in New York trading on Thursday morning.
ir.valeant.com/news-releases/2016/11-... Valeant Comments On Issued Philidor Criminal Charges November 17, 2016 LAVAL, Quebec, Nov. 17, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today learned that a criminal complaint was filed in relation to Philidor. Gary Tanner and Andrew Davenport were charged in the matter. The company, former CEO, former CFO, and current executives have not been charged at this time. Gary Tanner ceased to be a Valeant employee on September 13, 2015, and Andrew Davenport has never been an employee of the Company. The counts issued today include allegations that the charged parties engaged in actions to defraud Valeant as a company. Valeant continues to cooperate with all relevant authorities in this matter.
Ze maken Valeant wel echt kapot zo in het nieuws. Denk dat er nog meer gaat komen en dat 1 dollar voor het aandeel nog hoog is. Dit wordt Pharming 2.0
Takeda Pharmaceutical Co Ltd's (4502.T) negotiations to acquire Valeant Pharmaceuticals International Inc's (VRX.TO) Salix stomach-drug business have stalled over price disagreements, people familiar with the matter said on Wednesday. Shares of Valeant were down more than 8 percent at $15.71 on Wednesday after the Wall Street Journal reported that the talks had broken down. A deal for Salix would help Valeant trim the large debt pile it accumulated through aggressive acquisitions. Valeant had said on Nov. 1 that it was in talks with several parties about selling Salix. But on Tuesday, the Canadian company said it was expanding its sales force for Salix's key product, Xifaxin, among other drugs, suggesting plans to keep the business for the long term. The sources asked not to be identified because the negotiations are confidential. Valeant and Takeda declined to comment. Previous reports said that a sale of Salix could raise as much as $10 billion for Valeant, which has been struggling under a roughly $30 billion debt load after repeatedly slashing earnings expectations. Valeant's stock has declined more than 90 percent in the past year, erasing nearly $90 billion in market capitalization, over disclosures that it secretly worked with a specialty pharmacy to boost sales of its medicines. The company is the subject of multiple investigations by federal agencies and state prosecutors. Salix Pharmaceuticals makes treatments for disorders such as irritable bowel syndrome and diarrhea. Valeant's new chief executive officer, Joseph Papa, has committed to selling around $8 billion in non-core assets to help pay down debt that it accumulated over the course of a series of large acquisitions. Takeda tried earlier this year to buy Salix as part of a joint bid with private equity firm TPG, a few weeks before Papa took over as CEO. But Valeant's board rejected the offer as it wanted to give Papa time to map out a course for the company.
By Jonathan D. Rockoff and David Benoit Valeant Pharmaceuticals International Inc.'s talks to sell a stomach-drug business to Japan's Takeda Pharmaceutical Co. for roughly $10 billion have broken down amid last-minute disagreements over price and other matters, according to people familiar with the matter. Though the talks could still be revived, Valeant is now focused on building the business, Salix Pharmaceuticals, rather than selling it, the people said. The development represents another setback for a company that has been plagued by an accounting scandal, the departure of its top executives and a plummeting share price. As of Tuesday's close, Valeant shares had fallen 80% in the past year. Valeant is now moving ahead with plans to build the sales force for Salix's crown jewel, the irritable-bowel drug Xifaxan. Valeant announced the "significant" expansion in a news release Tuesday. Valeant's shares, which had already been sagging after Tuesday's announcement, fell further after The Wall Street Journal reported on the breakdown and were recently off more than 7%, at $15.92. One of the 11th-hour disputes was over the sum of an agreement, which Takeda sought to reduce, according to people familiar with the matter. Takeda, a big Japanese drugmaker that has prioritized stomach drugs, had approached the beleaguered Canadian pharmaceutical company about purchasing Salix and the sides been near a deal that would have included $8.5 billion in cash plus royalty payments, the Journal had reported earlier in November. That report sent Valeant's stock up 34%, but the gains have evaporated in recent weeks after a disappointing third quarter and another cut to its earnings guidance. Valeant is in the process of trying to sell several assets in its portfolio, which had been built largely through acquisitions, to pay down roughly $30 billion in debt. It is also exploring selling a surgical-equipment business that could fetch $2.5 billion, the Journal has reported. Valeant has said it hadn't intended to sell Salix, which it only bought last year and considers a core asset, but had to listen when a prospective bidder seemed willing to pay a good price. Some inside Valeant have argued against selling the unit because it is a potential source of significant sales growth, one of the people said. A sale would help Valeant pay off roughly $12 billion in bank debt, which is the most pressing concern for investors who fear a collapse in the company's earnings could put it at risk. And a purchase would help Takeda boost its stomach-drugs franchise. Takeda has sought several times to acquire Salix and Xifaxan, which Valeant had predicted could have $1 billion in sales this year. Takeda was a bidder for the company when Valeant won an auction for Salix in 2015, and earlier this year approached Valeant with a partner about buying the whole company, the Journal has reported. Xifaxan sales haven't done as well as some analysts expected, however. Many Salix sales representatives left the company, and Xifaxan has faced fierce competition from a competing drug, Viberzi, from Allergan PLC. Meanwhile, Teva Pharmaceutical Industries Ltd. also is working on a generic version of Xifaxan. Valeant hopes an expanded sales force will boost Xifaxan sales by targeting the primary-care doctors who often treat such conditions. But the company attributed its lower its earnings guidance in part to the expense of increasing its sales force. Write to Jonathan D. Rockoff at Jonathan.Rockoff@wsj.com and David Benoit at david.benoit@wsj.com (END) Dow Jones Newswires December 01, 2016 02:48 ET (07:48 GMT) © 2016 Dow Jones & Company, Inc. AAND TAKEDA PHARMACEUTICAL DE NOT JP3463000004 AAND VALEANT PHARMA INTERN AM NOT CA91911K1021 TAKEDA PHARMACEUTICAL CO LTD SPON ADR EA REPR 0.5 ORD US8740602052
Meltdown koers Valeant. Van $270 naar dieptepunt iets onder de $14. Thans $15. Om het circus draaiende te houden toen de koers in de $200 noteerde, werden de prijzen van medicijnen van Valeant in de VS omhoog geschroefd , wat zelfs de aandacht trok van Hillary Clinton. De mooie cijfers in 2014 kwamen vrijwel uitsluitend door prijsverhogingen in de VS. Valeant is het middelpunt geworden van overheidsinstanties VS en de SEC. Met donderend geraas is de koers in een kort tijdsbestek ingestort. Om het schip drijvende te houden , werd Salix in de verkoop gezet. Heeft nog niet geleid tot het gewenste resultaat. Dit bedrijf gaat tot het uiterste om hun inkomsten er beter uit te laten zien dan ze zijn. EPS adjusted is een toverwoord bij Valeant. Het Nederlandse navigatiebedrijf TT schermt ook met zulke begrippen.
Ze hadden nog beter even kunnen wachten om Ruconest terug te kopen.. binnenkort executieverkoop bij Valeant...
Dat denk ik niet... de naam Valeant is besmet... wegwezen daar... Binnenkort rechtzaak waar heel amerika alles via de media besmeurt krijgt... mediageile advocaat erop geklapt. Vanaf morgen (vanmiddag?) weg en handen vrij om zelf te sturen. Nogmaals: perfect timing zo!
IlIIIlIIIlIIIIIIlllllllIIII schreef op 7 december 2016 16:05 :
Dat denk ik niet... de naam Valeant is besmet... wegwezen daar...
Binnenkort rechtzaak waar heel amerika alles via de media besmeurt krijgt... mediageile advocaat erop geklapt.
Vanaf morgen (vanmiddag?) weg en handen vrij om zelf te sturen.
Nogmaals: perfect timing zo!
Mijn gedachte. Prima gedaan door S. de Vries en R. Wright.
Zo is het... ze hebben een enorme berg puin moeten ruimen wat ze zo in de schoot geworpen kregen. En nu zijn zij aan zet. Ik vind het knap... en nu wilde ik nog wat zeggen...maar wat was dat ook alweer?...
BCRX daarentegen... + 4.91%
Valeant Pharmaceuticals: We Were Wrong, Morgan Stanley Says By Ben Levisohn Valeant Pharmaceuticals International (VRX) has elected not to sell its Salix business–and that’s left Morgan Stanley analyst David Risinger and team with no choice but to cut the stock to Equal Weight from Overweight. They explain why: Since our upgrade in August, our investment thesis that management would stabilize the business and execute accelerated deleveraging via divestitures has been wrong. When we upgraded Valeant shares from EW to OW on August 17, 2016, we expected business stabilization and material divestitures. Neither has happened to date. Additionally, Valeant announced the departure of certain executives on Dec. 12 (see Executive departures an area of concern), and we no longer believe that shares can outperform. Although we have been disappointed in the progress, divestitures could still occur at any time, and management could enhance business performance. Risinger also lowered his price target on Valeant to $17 to “reflect the uncertainty.” Shares of Valeant Pharmaceuticals International have dropped 5.9% to $13.29. Valeant Pharmaceuticals International (VRX) has elected not to sell its Salix business–and that’s left Morgan Stanley analyst David Risinger and team with no choice but to cut the stock to Equal Weight from Overweight. They explain why: Since our upgrade in August, our investment thesis that management would stabilize the business and execute accelerated deleveraging via divestitures has been wrong. When we upgraded Valeant shares from EW to OW on August 17, 2016, we expected business stabilization and material divestitures. Neither has happened to date. Additionally, Valeant announced the departure of certain executives on Dec. 12 (see Executive departures an area of concern), and we no longer believe that shares can outperform. Although we have been disappointed in the progress, divestitures could still occur at any time, and management could enhance business performance. Risinger also lowered his price target on Valeant to $17 to “reflect the uncertainty.” Shares of Valeant Pharmaceuticals International have dropped 5.9% to $13.29. December 15, 2016, 9:57 A.M. ET
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)